| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by/(used in) investing activities | 5,346 | -45,943 |
| Proceeds from issue of ordinary shares | 15 | 15 |
| Net cash provided by financing activities | 15 | 15 |
| (decrease)/increase in cash and cash equivalents | -39,623 | -80,021 |
| Cash and cash equivalents at beginning of period | 121,330 | - |
| Effect of exchange rate changes on cash | 324 | - |
| Cash and cash equivalents at end of period | 82,031 | - |
Silence Therapeutics plc (SLN)
Silence Therapeutics plc (SLN)